This study evaluated whether cytokine-induced blood stem cell mobilization also mobilized lymphoma cells and whether lymphoma cell mobilization affected outcome post autologous blood stem cell transplant. Blood stem cell collections from 26 non-Hodgkin's lymphoma (NHL) patients harvested during steady-state (nonmobilized) and from 35 NHL patients harvested after cytokine administration (mobilized) were studied. The harvests were cultured and molecularly evaluated for clonal markers of the primary lymphoma. All patients underwent high-dose chemotherapy and autologous transplantation. Graft products from mobilized patients were more likely to contain lymphoma than graft products from non-mobilized patients (37% vs 19%) but this difference was not significant (P = 0.16). In a multivariate analysis, lymphoma contamination was not associated with patient age, gender, tumor grade, prior radiotherapy, duration of prior chemotherapy, mononuclear cell count, or the number of aphereses performed to obtain the product. Heavily pre-treated patients were less likely to have lymphoma-contaminated harvests (P = 0.064). Lymphoma contamination was positively associated with the number of progenitor cells collected (P = 0.047). In multivariate analyses, the only significant independent predictor of lymphoma contamination was the number of mononuclear cells collected (P = 0.031). Lymphoma contamination of transplanted apheresis products had no apparent impact on event-free and overall survival. Bone Marrow Transplantation (2001) 28, 207-212. Keywords: lymphoma; blood stem cell transplant; micrometastases; mobilization
cells.
1, 2 The pattern of tumor cell mobilization may vary by tumor type, since cancer cells have been reported to mobilize earlier than hematopoietic cells in breast cancer patients 1 but concomitantly with hematopoietic cells in myeloma patients. 2 The clonal and biologic potential of mobilized tumor cells upon reinfusion is unknown, although one study found no differences in the failure-free survival of low-grade lymphoma patients who received mobilized vs non-mobilized PBSC transplants. 3 Essentially, no reports exist regarding mobilization of lymphoma cells. The study described here evaluated factors which might affect both progenitor cell mobilization and lymphoma cell mobilization resulting in occult tumor cell contamination of autologous PBSC harvests and to evaluate the effect of contamination on the survival of autologous recipients of these harvests.
Patients and methods

Patient characteristics
Sixty-one patients with no histological evidence of bone marrow metastases, who received high-dose therapy and autologous PBSC transplant for non-Hodgkin's lymphoma (NHL) at the University of Nebraska Medical Center between July 1986 and December 1997, were included in this study. Inclusion also required that the patients all provided written informed consent for the evaluation of their blood stem cell harvests for lymphoma cells and that the tumors in question had an informative clonal marker. PBSC were collected from 26 of the patients during steady-state (non-mobilized group, 1986-1991) and from the other 35 patients after cytokine stimulation (mobilized group, 1991-1997). Twenty-two mobilized patients received G-CSF (filgrastim); 12 patients received GM-CSF (sargramostim); and one patient received PIXY-321 (a fusion protein of GM-CSF and interleukin 3). All patients had refractory or relapsed NHL at the time of cell collection. Data collected regarding these patients from medical records included characteristics of the final autologous graft product; the total number of aphereses performed for each patient and the total volume of blood processed, the total mononuclear cell count, CD34
+ cell count and granulocyte-monocyte progenitor (GM-CFC) count per kilogram patient weight. Patient characteristics considered included the NHL histologic subtype, the prior radiotherapy and chemotherapy history of each patient and the number of months each patient had received doses of combination chemotherapy before cell collection. The evaluation of PBSC collections for the presence of tumor cells was approved by the institutional review board. All patients whose PBSC collections were assayed for tumor cell presence were included in the analysis. The patients received the high-dose therapy appropriate for the histologic subtype of lymphoma at the time they were treated. Targets identifying an adequate non-mobilized stem cell collection consisted of eight 4-h collections for the first patient; thereafter the target consisted of 6.5-7 ϫ 10 8 mononuclear cells/kg donor weight. After April 1991, all patients received cytokines prior to the stem cell collection apheresis procedures, and the target became Ͼ1.1 ϫ 10 6 CD34 + cells/kg donor weight. G-CSF at a dose of 10 g/kg daily was the most frequently used mobilizing cytokine. GM-CSF at doses of 125-250 g/m 2 /day was employed as the initial mobilizing cytokine at the University of Nebraska Medical Center. In May 1996, G-CSF was substituted for GM-CSF as the standard mobilizing cytokine at a dose of 10 g/kg daily. One patient received PIXY-321 at a daily dose of 750 g for mobilization.
Prior therapy
Essentially all patients had received their initial anti-lymphoma therapy elsewhere and were referred to the University of Nebraska Medical Center at the time they became eligible for an autologous transplant. Whether a patient had ever received radiation therapy prior to PBSC collection was noted as was the number of combination chemotherapy regimens administered. Patients were evaluated in two subgroups: two or less or three or more chemotherapy regimens. Also, the total duration of chemotherapy for each patient was determined.
Culture and molecular tumor detection techniques
Apheresis samples were washed once with calcium and magnesium-free Hank's balanced salt solution (HBSS) and processed for initiation of cultures as described previously. 4 Briefly, flasks (25 cm 2 ) with 2 × 10 7 cells in 10 ml medium, with added phytohemagglutinin stimulated human spleen cell conditioned medium (1-2% by volume), were cultured in a 5% CO 2 in air atmosphere in a 37°C incubator to increase the sensitivity of lymphoma detection. Cytospin preparations were made from the cultures on a weekly basis, blind coded, and examined by the pathologist for morphologically abnormal cells. In addition, cells were processed for molecular analysis.
A proportion of each patient's apheresis harvest was studied by Southern or PCR analysis for clonality of immunoglobulin heavy-chain (J H ) and T cell ␥-receptor (CT B ) gene rearrangements matching those of the primary lymphoma, as described previously. 5 
Hematopoietic colony assays
Mobilization of progenitor cells was assessed employing in vitro hematopoietic colony-forming assays which identified granulocyte-monocyte/macrophage colony-forming cells (GM-CFC). The GM-CFC assay involved plating 3 ϫ 10 5 mononuclear cells separated from the harvest in 35-mm Petri dishes containing Iscove's modified Dulbecco's medium, (IMDM) 20% fetal bovine serum (FBS), 50 m 2-mercaptoethanol, 100 g/ml streptomycin, 100 U/ml penicillin, and 0.3% (wt/vol) agar supplemented with interleukin 3 (IL-3) (200 U/ml), GM-CSF (200 U/ml) and G-CSF (200 U/ml). Cultures were incubated at 37°C in a fully humidified atmosphere of 5% CO 2 in air for 14 days. Aggregates greater than 50 cells were counted as colonies.
Lymphoma histology
The histology of the primary lymphomas, based on the Working Formulation 6 was correlated with harvest positivity or negativity for lymphoma.
Sites of relapse
The sites of eventual relapse when available from the clinical record were correlated with sites of original disease and with the presence or absence of detectable lymphoma cells in the harvest received by the patient.
Data analysis
Fisher's exact test and the Wilcoxon test were used for comparing the patient and product characteristics. To test the significance of tumor contamination in both groups, Fisher's exact test and Wilcoxon tests were used. Finally, logistic regression analysis was performed to determine the independent predictors of tumor contamination. For this portion of the analysis, patients with unknown GM-CFC counts (n = 6) were excluded. One patient whose prior radiation history was unknown was assumed to have not received prior radiotherapy and one patient whose duration of prior chemotherapy was unknown was assumed to have received less than 6 months of chemotherapy. The actuarial event-free survival and overall survival of those patients who had lymphoma cells in their apheresis harvests were determined by the method of Kaplan and Meier and compared with that of patients whose harvests were lymphoma negative using the log rank test.
Results
Patient characteristics
Patient characteristics and their relationship to mobilization are shown in Table 1 . Patients who were cytokine mobilized were more likely to be female (P = 0.12) and were older (P = 0.022). Mobilized patients were more likely to have higher grade NHL (P = 0.019). Patients whose cells were mobilized were more likely to have received prior radiation therapy (P = 0.052). There was no association 209  Table 1 Characteristics of the non-Hodgkin's lymphoma patients studied between the number of prior chemotherapy regimens and mobilization (P = 1.0). However, the duration of prior chemotherapy was significantly longer for non-mobilized patients (P = 0.0063).
Product characteristics
The product characteristics are shown in Table 2 . While mobilized products were numerically more likely to contain tumor contamination than non-mobilized products, the association was not statistically significant (P = 0.16). Nonmobilized patients underwent significantly more apheresis procedures (P = 0.0001). The mobilized products contained more mononuclear cells (P = 0.0064) and had significantly higher GM-CFC counts (P = 0.0001) both per kg body weight and per liter of blood processed. 
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Correlates of lymphoma contamination
Lymphoma cell contamination of the apheresis products was not significantly associated with age (P = 0.33), gender (P = 0.58), tumor grade (P = 0.52), prior radiation therapy (P = 0.32), or duration of previous chemotherapy (P = 0.28). Heavily pre-treated patients (three or more previous chemotherapy regimens) were less likely to have lymphoma contamination in their product, although this trend was not statistically significant (P = 0.064). The trends associating lymphoma contamination with the number of mononuclear cells collected (P = 0.15) and the number of apheresis procedures (P = 0.14) were not significant. However, lymphoma contamination was associated with the number of GM-CFC collected (P = 0.047); products with higher values were more likely to contain detectable lymphoma cells. While heavily pre-treated patients had lower GM-CFC numbers (median 0.054 ϫ 10 4 kg/liter blood processed) in their apheresis products than patients who had received two or fewer prior chemotherapy regimens (median 0.080 ϫ 10 4 kg/liter blood processed), this difference was not statistically significant (P = 0.44). The results of univariate logistic regression on the 55 patients with known numbers of GM-CFC/kg in their collections shown in Table 3 revealed that age, gender, lymphoma grade, prior radiotherapy, number of prior chemotherapy regimens, and the duration of prior chemotherapy had no impact on lymphoma contamination in the apheresis products. Mobilization with cytokine increased the estimated relative risk of lymphoma contamination, although the difference was not statistically significant (P = 0.092). If the number of apheresis procedures was above the median, the risk of contamination was lower (P = 0.031). Based on multivariate analyses considering all factors in Table 3 , the only statistically significant independent predictor of lymphoma contamination was the number of mononuclear cells (MNC) in the product (P = 0.031). A collection of more than 0.13 ϫ 10 8 MNC/kg/l blood processed was associated with four times the risk of lymphoma contamination than a collection with fewer MNC. The relationship between lymphoma contamination in the apheresis product and event-free and overall survival is shown in Figures 1 and 2 (P = 1.00 and P = 0.90, respectively). There were no significant differences. Table 3 Estimated relative risks of lymphoma cell contamination in the apheresis products using univariate logistic regressions The most common histologic types of lymphoma in the entire patient group were diffuse large cell, immunoblastic and follicular lymphomas that together comprised about half the total in both patients who received transplant products containing detectable lymphoma cells and patients who received transplant products with no detectable lymphoma cells. Overall, the representation of high, intermediate and low grade lymphomas was 13%, 47% and 30%, respectively. In the patients receiving transplant products with detectable lymphoma cell, the representation of high, intermediate, and low grade lymphomas was 30%, 57% and 12%, respectively. In the patients receiving transplant products with no detectable lymphoma cells, the representation of high, intermediate and low grade lymphomas was 20%, 43% and 38%. Therefore, patients with high and intermediate grade lymphomas were more likely to have detectable lymphoma cells in the graft products whereas low grade lymphoma patients were over-represented in the group that did not have detectable tumor cells in their graft products.
Excluding two deaths occurring within 100 days of the transplant (from sepsis and myelodysplastic syndrome which occurred in one patient from the mobilized and one patient from the non-mobilized group) the sites of eventual relapses were evaluable in 14 patients in the non-mobilized group and 10 patients in the mobilized group. Two patients in the non-mobilized group relapsed in bone marrow. Both had received graft products with no detectable tumor cells. In the mobilized group, one patient with detectable tumor cells in the transplanted graft product relapsed in the bone marrow and a relapse was first detected in a blood smear in a patient who received a graft product that contained no detectable tumor cells. All other 20 patients relapsed at sites of previous disease.
Discussion
Questions have been raised for more than a decade about the presence and significance of tumor cells in blood stem cell harvests of candidates for autologous transplantation 4 and have been investigated in several studies. [7] [8] [9] [10] Sharp et al, 9 reported that the presence of lymphoma cells in the bone marrow harvest of patients with intermediate, or high grade NHL was associated with a less favorable outcome. The present non-randomized retrospective study evaluated factors influencing progenitor cell and tumor cell content of autologous apheresis products. In a multivariate analysis, lymphoma contamination of the apheresis harvest correlated significantly only with the number of mononuclear 211 cells in the apheresis products, suggesting that the likelihood of detecting tumor cells in the harvest is a function of the number of mononuclear cells collected and not a direct consequence of cytokine use. The numerically higher values of contaminated harvests from patients receiving cytokine for mobilization and the correlation with GM-CFC progenitors collected could have been a consequence of cytokine administration increasing the mononuclear cell and GM-CFC content of the harvest.
Cytokine administration with or without myelosuppressive chemotherapy is widely used for mobilization of blood stem cells. The optimum mobilizing strategy for PBSC has not been identified. An apheresis product should include a sufficient number of stem/progenitor cells necessary for optimum recovery of hematopoietic and immune function following transplantation. 11 One other important goal is that PBSC harvests contain minimal numbers of tumor cells. The results of this study showed that the products from mobilized patients contained more MNCs and had significantly higher GM-CFC counts. Also, multivariate analysis showed that the only statistically significant independent predictor of lymphoma cell contamination was the MNC count (P = 0.031). The event-free and overall survival of patients with or without detectable lymphoma cells in their harvests showed no differences, suggesting that lymphoma cells in PBSC graft products may not be clinically important and is compatible with observations that cytokine-induced mobilization does not affect the failure-free survival of low grade NHL patients who are treated with high-dose therapy and BSC transplantation. 3 Not all patients exhibit hematopoietic progenitor cell mobilization after administration of growth factors with or without myelosuppressive chemotherapy. Characteristics that have been associated with poor or no response to mobilization therapies include prior treatment with several cycles of chemotherapy, prior radiation therapy and presence of marrow metastases. 12, 13 Although previous cytotoxic chemotherapy and radiation therapy have been shown to negatively impact stem cell collection, 13 mononuclear cell and lymphoma cell mobilization were not affected by prior radiotherapy in the present study (P = 0.62 for MNC; P = 0.32 for lymphoma cells). The earlier study 13 included a significant number of patients with Hodgkin's disease, most of whom had previously received radiation therapy and this may have influenced the results. CD34 + cell numbers in the mobilized and non-mobilized collections in the present study could not be compared because CD34
+ data were not available for the non-mobilized group. A recently published study pointed out that quantifying progenitor cells in PBSC harvests using flow cytometric enumeration does not distinguish between viable and non-viable cells. In that study, viable CD34 + cells were detected by staining with annexin V FITC, because cell membrane asymmetry in early apoptosis exposed phosphatidylserine on the cell surface.
14 Stem cells damaged by prior chemoradiotherapy might exhibit increased apoptosis, resulting in decreased numbers of progenitor cells in the harvests of patients who were more heavily pre-treated. Similar biological factors could underlie the observation that lymphoma cells in the apheresis harvests were not associated with an adverse clinical outcome. Lymphoma
Bone Marrow Transplantation cells in bone marrow associate with the stromal cells and these associations suppress apoptosis and confer chemoresistance. 15 Detachment of the lymphoma cella from stromal cells, which could occur during tumor cell mobilization, promotes apoptosis. 16 Potentially, therefore, lymphoma cells in apheresis harvests may be prone to apoptosis rendering them clinically unimportant. Alternatively, lymphoma cells in the harvest may not be important clinically if the majority of relapses originate from lymphoma cells that survive in the patient despite high-dose therapy. The patterns of relapse observed in the study reported here confirm previous observations that relapses occur primarily at sites of previous disease. 17 This study suggests that collecting blood stem cell autologous products from patients with NHL with the least likelihood of tumor cell contamination is best accomplished by optimizing mobilization techniques to permit harvesting more stem cells with the smallest number of mononuclear cells using the least number of aphereses. This information may be useful as PBSC mobilization techniques continue to be refined in order to collect cells with the greatest efficiency that have optimum effectiveness.
